Our Firm is currently evaluating a number of possible legal claims on behalf of individuals who were allegedly harmed by Byetta and other incretin mimetics. As such, we are monitoring this litigation closely.
New York, New York (PRWEB) October 08, 2014
The federal judge overseeing dozens of Byetta lawsuits (http://www.byettalawsuit.com ) and other product liability claims involving incretin mimetic diabetes drugs has denied a request by plaintiffs’ to compel defendants to produce source documents pertaining to adverse event reports involving the medications. In an Order issued on October 6, 2014, U.S. District Judge Anthony J. Battaglia of the Southern District of California stated that the documents were irrelevant to the issues of preemption and causation, and that compelling their production would impose an undue burden on the defense. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)
“Our Firm is currently evaluating a number of possible legal claims on behalf of individuals who were allegedly harmed by Byetta and other incretin mimetics. As such, we are monitoring this litigation closely,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Byetta lawsuit evaluations to patients who may have been harmed by this drug.
Incretin Mimetics Litigation
According to court documents, lawsuits involving Byetta and other incretin mimetics have been mounting since March 2013, when the U.S. Food & Drug Administration (FDA) announced it was reviewing findings from an unpublished study that indicated their use could be associated with precancerous changes in the cells of the pancreas. Though the agency has been unable to conclude that such a link exists, its review is ongoing.
Court records indicate that Judge Battaglia is currently overseeing more than 480 incretin mimetic claims in the Southern District of California, where all federally-filed lawsuits involving the medications have been consolidated for coordinated pretrial proceedings. All of the lawsuits allege that the use of drug like Byetta, Victoza and Januvia caused patients to develop pancreatic cancer. The complaints further allege that the various manufacturers of incretin mimetics failed to warn doctors and patients about their potentially harmful effects on the pancreas, as well as their alleged association with an increased risk of pancreatic cancer.
In addition to the claims pending in the federal proceeding, court documents show that a number of Byetta lawsuits involving similar allegations have been consolidated in a state-level litigation underway in California Superior Court. (In re: Byetta Cases, JCCP No. 4574)
Individuals who used Byetta or another incretin mimetic may be entitled to file their own lawsuit if they were diagnosed with pancreatitis, pancreatic cancer or thyroid cancer. To learn more about filing a Byetta lawsuit, please visit Bernstein Liebhard LLP’s website. For a free legal review, please call 800-511-5092.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter
Felecia L. Stern, Esq.
Bernstein Liebhard LLP